Labcorp — Jul 30, 2026 release

(6) Adjusted Operating Income and margin increased, driven by organic growth and operating efficiencies from the strategic actions taken in Early Development. As of June 30, 2026 Metrics Summary (Dollars in billions) TTM Net Orders $ 3.32  TTM Book to Bill 1.03  Backlog $ 8.73  (7) Next Twelve Months Forecast Backlog Conversion $ 2.75  (7) Backlog increased 0.2% compared to this period last year. 7 Guidance for 2026 Labcorp is updating 2026 full year guidance to reflect its second quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of June 30, 2026. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases, and dividends. (Dollars in millions, except per share data) Previous Updated 2026 Guidance 2026 Guidance Low High Low High Revenue Labcorp Enterprise (1)(2) $14,649 $14,803 $14,710 $14,827 Growth (3) 5.0% 6.1% 5.4% 6.3% Diagnostics Laboratories $11,431 $11,518 $11,450 $11,532 Growth (3) 5.1% 5.9% 5.3% 6.0% Biopharma Laboratory Services (4) $3,216 $3,266 $3,269 $3,300 Growth (3) 3.8% 5.4% 5.5% 6.5% Adjusted EPS $17.70 $18.35 $18.10 $18.55 Free Cash Flow $1,240 $1,360 $1,240 $1,360 (1) 2026 Updated Enterprise guidance includes an impact from foreign currency translation of 0.4%. (2) Enterprise level revenue is presented net of intercompany transaction eliminations. (3) Growth based on 2025 Enterprise revenue of $13,952 million, Diagnostics Laboratories revenue of $10